Most women know that pharmaceutical birth control does not protect against STDs. But did you know that certain forms of birth control can actually increase your risk for contracting human immunodeficiency virus (HIV), which if left untreated, may progress to the deadly disease known as acquired immunodeficiency syndrome (AIDS)?
Depo-Provera (also referred to as DMPA, or DMPA-IM), a brand of birth control that is often referred to as “the birth control shot,” is one such form of birth control that introduces so much risk for users, that a group of doctors and researchers have petitioned the FDA for its complete removal from the market. While all forms of pharmaceutical birth control come with side effects, the FDA petitioners claim the health complications of the Depo-Provera birth control shot are too high to justify the benefits of pregnancy prevention.
The doctors and researchers who petitioned the FDA presented evidence that conclusively shows that Depo-Provera is responsible for increased transmission of HIV from men to women. Again, if left untreated, HIV will progress to the extremely deadly disease known as AIDS.
According to UNAIDS, between 31.6 million and 44.5 million people globally were living with HIV in 2019. An estimated 500,000 to 970,000 people globally died from AIDS-related illnesses in 2019. Sub-Saharan Africa alone contains more than two-thirds of all people living with HIV globally. Notably, according to data from the United Nations, Depo-Provera is the most popular method of contraception in Sub-Saharan Africa.
A 2016 meta-analysis of global survival rates from HIV diagnosis to AIDS onset, and from AIDS onset to death, found that “the majority of HIV-positive patients progress to AIDS within the first decade of diagnosis. Most patients who receive highly active antiretroviral therapy (HAART) will survive for >10 years after the onset of AIDS, whereas the majority of the patients who do not receive HAART die within 2 years of the onset of AIDS.”
Despite significant advances in HAART, HIV is clearly still an extremely serious and deadly disease. And although Depo-Provera carries the increased risk of HIV transmission, this side effect is currently not reported by mainstream sources of contraceptive information, such as Planned Parenthood. Notably, when discussing the side effects and disadvantages of Depo-Provera, Planned Parenthood also neglects to mention another serious, well-established risk of the birth control shot: bone mineral density loss, which leads to an increased risk of bone fractures and osteoporosis later in life for women.
Depo-Provera and the link to increased HIV transmission
“four meta-analyses (3 reports, one of which is known as the 2015 Morrison SRMA trial) were published in 2015. Each used different inclusion criteria and compiled the data on different numbers of studies, yet all 4 came up with essentially the same result of significantly increased risk of male-to-female HIV transmission in women using DMPA. . . Importantly, no consistent association has emerged with regard to oral contraceptives or other injectable or implantable contraceptives and the facilitation of HIV transmission.”
In contrast, organizations that downplay the risk of HIV for Depo-Provera users cite a study known as the ECHO Trial study which was conducted between Dec 2015 and Sept 2017 to examine the risk of HIV acquisition by women using the Depo-Provera birth control shot. Published in The Lancet in June 2019, the study concluded that the ECHO Trial Consortium of researchers “did not find a substantial difference in HIV risk among the methods evaluated [including Depo-Provera, the copper IUD, and the levonorgestrel implant], and all methods were safe and highly effective.”
According to the authors of the Citizen’s Petition to the FDA, ECHO’s conclusion is erroneous and also potentially disingenuous:
“a careful analysis of the design and results of the ECHO Trial reveals that in fact, the ECHO Trial results of 2019 provide a near perfect confirmation of the results of the 2015 Morrison SRMA trial, and that the authors misrepresent them as the opposite; as the exculpation of DMPA as ‘safe.’”
Closer inspection of their analysis reveals that the ECHO researchers decided that they would only consider a 50% increase in HIV risk as “meaningful” on the basis of “formative work with stakeholders to determine a meaningful difference that would inform policy change.” Thus, they instead advocate for “continued and increased access to these contraceptive methods.”
Understanding the ECHO study on Depo-Provera users
As it happens, the ECHO study did find that compared to the use of the levonorgestrel implant, Depo-Provera use was associated with an increased risk of HIV infection (with a hazard ratio of 1.29, as seen in their “continuous use” dataset in Table 2, almost identical to the Morrison SRMA trial, which concluded an increased HIV risk with Depo-Provera use). However, the study wasn’t statistically powered to measure the percent increased risk of hazard ratios below 1.3 (which would indicate a 30% increased risk). So while we can’t conclude with certainty from these data what exactly the increased HIV infection risk of Depo-Provera is, it does seem that there is at least some increased level of risk (especially when considered with other robust studies which have indicated similar levels of increased risk), despite the ECHO Consortium’s insistence to the contrary.
In the ECHO study, the exact level of risk has been obscured for unknown reasons, making it difficult for women to get accurate information about HIV risk and Depo-Provera.
Since other robust studies have indicated an increased risk of contracting HIV for Depo-Provera users—even if it’s less than a 50% increase—women should be informed of it so that they may consent to taking the risk. Greater transparency about birth control risks is, in fact, what motivated the Citizen’s Petition writers to urge the FDA that, of all the birth control methods available, Depo-Provera should be removed from the market.
Given how many highly effective methods of birth control are available to women today, there is little justification for downplaying the risks women face by receiving the Depo-Provera birth control shot. If you have had a negative experience with the birth control shot, we encourage you to submit your experience as a comment on the FDA petition.
Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, and Overbaugh J. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771–1777.
Brind J, Condly SJ, Mosher SW, Morse AR, and Kimball J. Risk of HIV infection in Depot Medroxyprogesterone Acetate (DMPA) users: a systematic review and meta-analysis. Issues Law Med 2015; 30:129–139.
Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, Nunn A, Chisembele M, Ramjee G, Rees H, and McCormack S. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod 2014; 29:1810–1817.
Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, and Hapgood JP. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS One 2014; 9:e96497.
Hapgood JP and Tomasicchio M. Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis. Arch Virol 2010; 155:1009-1019. Doi: 10.1007/s00705-010-0678-0.
Hapgood JP, Ray RM, Govender Y, Avenant C, and Tomasicchio M. Differential glucocorticoid receptormediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesis. Am J Reprod Immunol 2014; 71(6):505–512. Doi: 10.1111/aji.12214.
Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis 2012; 12:19–26.
Huijbregts RP, Michel KG and Hel Z. Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception 2014 Aug; 90(2):123–129. Doi: 10.1016/j.contraception.2014.02.006.
Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Lutalo T, Meehan M, Xianbin, Gray RH; Rakai Project Study Group. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003; 17:233–240.
Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, and McIntyre JA. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007; 75:461–467.
Maritz MF, Ray RM, Bick AJ, Tomasicchio M, Woodland JG, Govender Y, Avenant C, and Hapgood JP. Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels. PLoS One 2018 https://doi.org/10.1371/journal.pone.o196043.
McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, and Padian NS. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013; 27:1001–1009.
Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, Mugerwa R, Padian N, Rugpao S, Brown JM, Cornelisse P, Salata RA; Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85–95.
Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, Patel S, Ahmed K, Ramjee G, Friedland B, and Lahteenmaki P.. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS 2012; 26:497–504.
Morrison CS, Chen P-L, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, and Low N. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015; 12:e1001778. doi: 10.1371/journal.pmed.1001778.
Myer L, Denny L, Wright TC, and Kuhn L. Prospective study of hormonal contraception and women’s risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166–174.
Ralph LJ, McCoy SI, Shiu K and Padian NS. Hormonal contraceptive use and women’s risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis 2015; 15:181–189. Doi: 10.1016/S1473-3099(14)71052–1057.
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, and Thijssen JH. Classification and pharmacology of progestins. Maturitas 2003; 46 (Suppl 1):S7-S16. Doi: 10.1016/j.maturitas.2003.09.014.
Tomasicchio, Michele, Avenant C, Du Toit A, Ray RM, and Hapgood JP. The Progestin-Only Contraceptive Medroxyprogesterone Acetate, but Not Norethisterone Acetate, Enhances HIV-1 Vpr-Mediated Apoptosis in Human CD4+ T Cells through the Glucocorticoid Receptor. PloS One 2013; 8:e62895.
Wand H and Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS 2012; 26:375–380.
For more on HIV risk and the birth control shot, see the articles below.